# US 2021/0171585 A1 · Antimicrobial peptide id13, preparation method and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171585 A1
- Document ID: US20210171585A1
- Status: Published application
- Kind: A1
- Application number: 17/078,613
- Filed: 2020-10-23
- Published: 2021-06-10
- Earliest claimed: 2019-12-04
- Assignees: Feed Research Institute, Chinese Academy of Agricultural Sciences
- Applicants: Feed Research Institute, Chinese Academy of Agricultural Sciences
- Inventors: Jianhua WANG; Bing LI; Da TENG; Ruoyu MAO; Xiumin WANG; Ya HAO; Na YANG
- Web page: https://patentgrep.com/patent/US20210171585A1

## CPC

- C07K 14/39: from yeasts
- C07K 14/43577: {from flies}
- C12N 1/16: Yeasts; Culture media therefor
- C12N 15/815: {for yeasts other than Saccharomyces}
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C07K 2319/50: containing protease site
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

The present invention provides an antimicrobial peptide ID13 (with a sequence set forth in SEQ ID No. 1), a preparation method and use thereof. The antimicrobial peptide ID3 is successfully expressed in Pichia pastoris using genetic engineering technology. The antimicrobial peptide ID13 of the present invention has an excellent bactericidal activity against Gram-positive bacteria such as Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus suis, and has a low hemolytic activity against mouse red blood cells and a low murine macrophage cytotoxicity.

## Claims

### Claim 1

An antimicrobial peptide ID13 comprising a sequence set forth in SEQ ID No: 1.

### Claim 2 (depends on 1)

A DNA sequence encoding the antimicrobial peptide ID13 of claim 1.

### Claim 3 (depends on 2)

The DNA sequence of claim 2, comprising a nucleotide sequence set forth in SEQ ID No. 3.

### Claim 4 (depends on 2)

The DNA sequence of claim 2, wherein the DNA sequence is present in a recombinant yeast expression vector.

### Claim 5 (depends on 4)

The DNA sequence of claim 4, wherein the recombinant yeast expression vector is linearized and transformed into Pichia pastoris X-33.

### Claim 6 (depends on 2, 5)

The DNA sequence of claim 5, wherein Pichia pastoris X-33 is cultured by a method comprising
1) preparing a seed solution, wherein a single colony of a yeast transformant comprising the the DNA sequence of claim 2 is picked from a YPD plate and seeded into a 10 ml YPD liquid medium comprising 100 μg/mL zeocin, cultured on a shaker for 18-24 h at 29° C., 250 rpm, then seeded into a 200 mL YPD liquid medium with a seeding mount of 1%, cultured on a shaker for 16-18 h at 29° C., 250 rpm, until an OD600 nm of 6 is reached, so as to obtain the seed solution;
2) carrying out a fermentation culture, wherein the seed solution obtained in step 1) is added into a 2 L basal salt medium with a seeding mount of 10% at 25° C.˜29° C., adjusting pH of the medium to 5.0, adding 9.6 ml PMT1, maintaining an aeration of 8 vvm, a rotation rate of 600 rpm, and a dissolved oxygen amount of 20% or more;
3) feeding a carbon source, wherein when the dissolved oxygen first decreases slowly and then rises suddenly to 80% or more, a 50% glucose solution with 12‰ PMT1 is added in a fed-batch culture at a rate of 12-24 mL/L/min for 6-8 h, with an increased rotation rate of 1000 rpm;
4) inducing by methanol, wherein after the glucose is added, the fungus is starved for half an hour, adding 100% methanol and culturing at a gradually increased fed-batch rate from 1 mL/L/min in the first hour to 6 mL/L/min in the sixth hour, an increased rotation rate of 1100 rpm, an increased pH of 5.5, and a dissolved oxygen amount maintained at 20% or more, until the end of fermentation; wherein, the basal salt medium used in step 2) comprising 45 g glucose, 50 g NH4H2PO4, 20 g K2SO4, 15 g MgSO4.7H2O, 6 g KH2PO4, 0.4 g CaSO4 and 1.5 g KOH, and water in a final volume of 1 L.

### Claim 7 (depends on 5)

The DNA sequence of claim 5, wherein Pichia pastoris X-33 is subject to a fermentation culture to secrete the antimicrobial peptide ID13.

### Claim 8 (depends on 1)

A method for treating an anti-pathogenic bacterium infection in a subject, comprising administering to the subject a therapeutically effective amount of the antimicrobial peptide ID13 of claim 1, wherein the pathogenic bacterium is selected from Staphylococcus aureus, Streptococcus pneumoniae, and Streptococcus suis.
